Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 9, 2004 - Issue 1
Submit an article Journal homepage
112
Views
82
CrossRef citations to date
0
Altmetric
Review

Advances in pharmacotherapy for tobacco dependence

Jonathan Foulds UMDNJ-School of Public Health, 317 George Street, Suite 210, New Brunswick, NJ 08901, USA. [email protected]
,
Michael Burke UMDNJ-School of Public Health, 317 George Street, Suite 210, New Brunswick, NJ 08901, USA. [email protected]
,
Michael Steinberg UMDNJ-School of Public Health, 317 George Street, Suite 210, New Brunswick, NJ 08901, USA. [email protected]
,
Jill M Williams
&
Douglas M Ziedonis
Pages 39-53 | Published online: 02 Mar 2005

Bibliography

  • DEPARTMENT OF HEALTH AND HUMAN SERVICES: Reducing Tobacco use: A Report of the Surgeon General Atlanta (CA). US Department of Health and Human Services, Office on Smoking and Health. (2000).
  • ROYAL COLLEGE OF PHYSICIANS: Nicotine Addiction in Britain: A Report of the Tobacco Advisory Group of the Royal College of Physicians. Royal College of Physicians of London, London (2000).
  • THE WORLD BANK: Curbing the Epidemic: Governments and the Economics of Tobacco Control. The International Bank for Reconstruction and Development/The World Bank, Washington DC, USA (1999).
  • FIORE MC, BAILEY WC, COHEN SJ et al.: Treating Tobacco Use and Dependence: Clinical Practice Guideline. US Department of Health and Human Services, Public Health Service, Rockville, MD, USA (2000).
  • HUGHES JR, KEELY J, NAUD S: Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction (2004) 99(1):29–38.
  • WORLD HEALTH ORGANIZATION: International Statistical Classification of Diseases and Related Health Problems (lOth revision). WHO, Geneva (1992).
  • AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and statistical manual of mental disorders (4th edition). American Psychiatric Association, Washington, USA (1995).
  • SILAGY C, LANCASTER T, STEAD L, MANT D, FOWLER G: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev (2002) (4):CD000146.
  • HAJEK P, WEST R, FOULDS J, NILSSON F, BURROWS S, MEADOWS A: Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch. Intern. Med. (1999) 159(17):2033–2038.
  • WEST R, HAJEK P, FOULDS J, NILSSON F, BURROWS S, MEADOWS A: A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (2000) 149:198–202.
  • HUGHES JR, STEAD LF, LANCASTER T: Antidepressants for smoking cessation. Cochrane Database Syst. Rev (2003) (1):CD000031.
  • CRYAN JF, GASPARINI F, VAN HEEKE G, MARKOU ATHINA: Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond buproprion. Drug Discov. Today (2003) 8(22):1025–1034.
  • GEORGE TP, O'MALLEY SS: Current pharmacological treatments for nicotine dependence. Trends Pharmacol. Sci. (2004) 25(1):42–48.
  • •Good recent review of pharmacological treatments.
  • BURTON SL, GITCHELL JG, SHIFFMAN S: Use of FDA-approved pharmacologic treatments for tobacco dependence - United States, 1984-1998. Morb. Mortal. Wkly Rep. (2000) 49(29):665–668.
  • MCNEILL A, FOULDS J, BATES C: Regulation of nicotine replacement therapies (NRT): a critique of current practice. Addiction (2001) 96:1757–1768.
  • •Good critique of current regulations for nicotine replacement therapies.
  • HAJEK P, JARVIS MJ, BELCHER M, SUTHERLAND G, FEYERABEND C: Effect of smoke-free cigarettes on 24 h cigarette withdrawal: a double blind placebo-controlled study. Psychopharmacology (Berl) (1989) 97(1):99–102.
  • FOULDS J, RAMSTROM L, BURKE M, FAGERSTROM K: The effect of smokeless tobacco (snus) on public health in Sweden. Tob. Control (2003) 12:349–359.
  • BENOWITZ NL: Snuff, nicotine and cardiovascular disease: implications for tobacco control.' Am. Coll Cardiol (1999) 34(6):1791–1793.
  • BENOWITZ NL, JACOB P 3rd: Effect of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clin. Pharmacol Ther. (2000) 67(6):653–659.
  • FOWLER JS, LOGAN J, WANG GJ, VOLKOV ND: Monoamine oxidase and cigarette smoking. Neurotoxicology (2003) 24(1):75–82.
  • ROSE JE, BEHM FM, RAMSEY C, RITCHIE JC: Platelet monoamine oxidase, smoking cessation and tobacco withdrawal symptoms. Nicotine Tob. Res. (2001) 3:383–390.
  • GOURLAY SG, STEAD LF, BENOWITZ NL: Clonidine for smoking cessation. Cochrane Database Syst. Rev (2000) (2):CD000058.
  • SHYTLE RD, PENNY E, SILVER AA, GOLDMAN J, SANBERG PR: Mecamylamine (Inversine): an old antihypertensive with new research directions." Hum. Hypertens. (2002) 16(7):453–457.
  • WEST R: Glucose for smoking cessation: does it have a role? CNS Drugs (2001) 15(4):261–265.
  • BERLIN I, SAID S, SPREUX-VAROQUAUX 0 et al: A reversible monoamine oxidase a inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin. Pharmacol Ther. (1995) 58 (4) :444–452.
  • DAVID S, LANCASTER T, STEAD LF: Opioid antagonists for smoking cessation. Cochrane Database Syst. Rev (2001) (3):CD003086.
  • BIBERMAN R, NEUMANN R, KATZIR I, GERBER Y: A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction (2003) 98(10):1403–1407.
  • •Promising results from selegiline in this trial.
  • HUGHES JR, STEAD LF, LANCASTER T: Anxiolytics for smoking cessation. Cochrane Database Syst. Rev (2000) (4):CD002849.
  • Pfizer unveils anti-smoking drug. Wall Street Journal (2003).
  • SLATER YE, HOULIHAN LM, MASKELL PD et al.: Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology (2003) 44(4):503–515.
  • KEM WR: The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav. Brain Res. (2000) 113(1-2):169–181.
  • KITAGAWA H, TAKENOUCHI T, AZUMA R et al.: Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology(2003) 28(3):542–551.
  • GROTTICK AJ, TRUBE G, CORRIGALL WA et al: Evidence that nicotine alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J Pharmacol Exp. Ther. (2000) 294(3):1112–1119.
  • MARKOU A, PATERSON NE: The nicotine antagonist mathyllcacotinine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob. Res. (2001) 3(4):361–373.
  • LAVIOLETTE SR, VAN DER KOOY D: The motivational valence of nicotine in the rat tegmental area is switched from rewarding to aversive following blockade of the alpha-7 subunit-containing nicotine acetylcholorine. Psychopharmacology (2003) 166(3):306–313.
  • LAVIOLETTE SR, VAN DER KOOY D: The neurobiology of nicotine addiction: bridging the gap from molecules to behavior. Nat. Rev. Neurosci. (2003) 166(3):306–313.
  • MURPHY ME HEY K, JOHNSTONE E: Bromocriptine use is associated with decreased smoking rates. Addict. Biol. (2002) 7(3):325–328.
  • JARVIK ME, CASKEY NH, WIRSHING WC: Bromocriptine reduces cigarette smoking. Addiction (2000) 95(8):1173–1183.
  • GEORGE TP, VESSICCHIO JC, TERMINE A: A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol. Psychiatry (2003) 53(2):136–143.
  • MILLER DK, WONG EH, CHESNUT MD, DWOSKIN LP: Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp. Ther. (2002) 302(2):687–695.
  • RAUHUT AS, MULLINS SN, DWOSKIN LP, BARDO MT: Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol. Exp. Ther. (2002) 303 (2):664–672.
  • KLIMEK V, ZHU MY, DILLEY G et al: Effects of long-term cigarette smoking on the human locus coeruleus. Arch. Gen. Psychiatry (2001) 58:821–827.
  • EPSTEIN AM, KING AC: Naltrexone attenuates acute cigarette smoking behavior. Pharmacol Biochem. Behav. (2004) 77(1):29–37.
  • COHEN C, PERRAULT G, VOLTZ C, STEINBERG R, SOUBRIE P: 5R141716A, a central cannabinoid receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav. Pharmacol (2002) 13:451–463.
  • TZAVARA EY, DAVIS RJ, PERRY KW et al: The CB1 receptor antagonist 5R141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. BE J Pharmacol. (2003) 138:544–553.
  • ANTHENELLI RM, DESPRES JP: Effects of Rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US Trial (Smoking Cessation in Smokers Motivated to Quit). American College of Cardiology 53rd Annual Scientific Session, New Orleans, LA, USA (2004).
  • WEST R, WILLIS N: Double-blind placebo controlled trial of dextrose tablets and nicotine patch in smoking cessation. Psychopharmacology (Berl) (1998) 136(2):201–204.
  • WEST R, COURTS S, BEHARRY S, MAY S, HAJEK P: Acute effect of glucose tablets on desire to smoke. Psychopharmacology (Ben.) (1999) 147(3):319–321.
  • •Impressive results from oral glucose in this trial.
  • MCROBBIE H, HAJEK P: Effect of glucose on tobacco withdrawal symptoms in recent quitters using brupopion or nicotine replacement. Hum. Psychopharmacol (2004) 19: 57–61.
  • HARAKAS P, FOULDS J: Acute effects of glucose tablets on craving, withdrawal symptoms, and sustained attention in 12-h abstinent tobacco smokers. Psychopharmacology (Berl.) (2002) 161(3):271–277.
  • WEST R: Glucose therapy: role and efficacy. Italian Socieg, of Pulmonary Medicine, Rome (2003).
  • SHIFFMAN S, FANT RV, GITCHELL JG et al: Nicotine delivery systems: how far has technology come? Am. J. Drug Deify. (2003) 1(2):112–124.
  • D'ORLANDO K, FOX B: Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw a novel nicotine replacement product. Nicotine Tob. Res. (2004) 6:63–70.
  • RUSSELL MAH, JARVIS MH, FEYERBRAND C, FERNO 0: Nasal nicotine solution: a potential aid to giving up smoking? BE Med. J. (1983) 286:683–684.
  • FANT RV, HENNINGFIELD JE, SHIFFMAN S, STRAHS KR, REITBERG DP: A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem. Behav. (2000) 67:479–482.
  • MCNEIL CONSUMER HEALTHCARE: Nicotrol Inhaler: mean nicotine concentrations after a 1 mg dose of nicotrol NS (=30). Physician's Desk Reference (2001) 55:1828.
  • WESTMAN EC, TOMLIN KF, PERKINS CE: Oral nicotine solution for smoking cessation: a pilot tolerability study. Nicotine Tob. Research (2001) 3:391–396.
  • PARK CR, MUNDAY DL: Development and evaluation of a biphasic buccal adhesive tablet for nicotine replacement therapy. Int. Pharm. (2002) 237:215–226.
  • NIAURA R, SAYETTE M, SHIFFMAN S et al.: Comparative efficacy of rapid-release nicotine gum versus nicorette in relieving smoking cue -provoked craving. Socieg, for Research on Nicotine and Tobacco 9th Annual Meeting, New Orleans, LA, USA (2003).
  • FOULDS J, RUSSELL MAH, JARVIS MJ,FEYERABEND C: Nicotine absorption and dependence in unlicensed lozenges available over the counter. Addiction (1998) 93:1427–1431.
  • HUGHES JR, LESMES GR, HARSUKAMI DK et al.: Are higher doses of nicotine replacement more effective for smoking cessation. Nicotine Tob. Res. (1999) 1:169–174.
  • JORENBY DE, SMITH SS, FIORE MC et al: Varying nicotine patch dose and type of smoking cessation counseling. JAMA (1995) 274:1347–1352.
  • TONNESEN P, PAOLETTI P, GUSTAVSSON G et al.: Higher dosage nicotine patches increase one-year smoking cessation rates; results from the Collaborative European Anti-Smoking Evaluation (CEASE) trial. Eur. Respir. (1999) 13:238–246.
  • SWEENEY CT, FANT RV, FAGERSTROM KO et al: Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs (2001) 15:453–467.
  • FAGERSTROM KO, SCHNEIDER NG, LUNELL E: Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for nicotine withdrawal symptoms. Psychopharmacology (Berl) (1993) 111:271–277.
  • WENNIKE P, DANIELSSON T, LANDFELDT B et al.: Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction (2003) 98(10):1395–1402.
  • LASSER K, BOYD JW, WOOLHANDLER S, HIMMESTEIN DU, MCCORMICK D, BOR DH: Smoking and mental illness: A population-based prevalence study. JAMA (2000) 284:2606–2610.
  • GEORGE TP, ZIEDONIS DM, FEINGOLD A et al: Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am. J. Psychiatry (2000) 157(10:1835–1842.
  • LERMAN C, NIURA R: Applying geneticapproaches to the treatment of nicotine dependence. Oncogene (2002) 21:7412–7420
  • •Good review of genetic approaches to nicotine dependence.
  • PENTEL PR, MALIN DH, ENNIFAR S et al.: A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats; Pharmacol Bioch. Behav. (2000) 65(1):191–198.
  • SATOSKAR SD, KEYLER DE, LESAGE MG: Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int. Immunopharmacol (2003) 3:957–970.
  • FOX BS, KANTAK KM, EDWARDS MA et al.: Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med. (1996) 2:1129–1132.
  • CLAIR-ROBERT J, AKERS CVR, VANHINSBERGH L, MCKENNA KA, WOOD DM, JACK L: Longitudinal safety and immunogenicity data of TA-NIC, a novel nicotine vaccine. Socieg, for Research on Nicotine and Tobacco 9th Annual Meeting, New Orleans, LA,USA (2003) (Abstract).
  • LINDMAYER K, HORWITH G, FATTOM A et al.: Results of a Phase I, double-blinded, controlled safety and immunogenicity trial of NICVAX, a conjugated nicotine vaccine. Society for Research on Nicotine and 9th Annual Meeting, New Orleans, LA,USA (2003) (Abstract).
  • SLOTKIN TA: Fetal nicotine or cocaine exposure; which one is worse?' Pharmacol Exp. Ther. (1998) 285(3):931–945.
  • KEYLER DE, SHOEMAN D, LESARGE MG, CALVIN AD, PENTEL PR: Maternal vaccination against nicotine reduces nicotine distribution to fetal brain in rats. J. Pharmacol Exp. Ther. (2003) 305(2):587–592.
  • STEAD LF, LANCASTER T: Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst. Rev (2002) (3):CD001007.
  • STEAD LF, LANCASTER T, PERERA R: Telephone counseling for smoking cessation. Cochrane Database Syst. Rev (2003) (1):CD002850.
  • MACLEOD ZR, CHARLES MA, ARNALDI VC, ADAMS IM: Telephone counselling as an adjunct to nicotine patches in smoking cessation: a randomised controlled trial. Med. J. Aust. (2003) 179(7):349–352.
  • RIGOTTI NA, MUNAFO MR, MURPHY ME STEAD LF: Interventions for smoking cessation in hospitalized patients. Cochrane Database Syst. Rev (2003) (1):CD001837.
  • ZIEDONIS DM, GEORGE TP: Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr. Bull. (1997) 23(2):247–254.
  • HALL SM, REUS VI, MUNOZ RF et al:Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry (1998) 55(8):683–690.

Websites

  • http://www.treatobacco.net Database and education resource for treatment of tobacco dependence.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.